| Entries |
| Document | Title | Date |
|---|
| 20080241190 | VACCINATION OF HORSES AGAINST LAWSONIA INTRACELLULARIS - The present invention is broadly concerned with vaccination of horses against proliferative enteritis, preferably equine proliferative ileitis, which is caused by an obligate intracellular bacterium Lawsonia Intracellularis (L. intracellularis). Specifically, the invention provides for a method of providing immune protection against L. intracellularis by vaccinating horses, preferably foals starting from one (1) week of age. Preferably the foals are vaccinated with about 4.9 log 10 to about 6.9 log 10 of a live modified L. intracellularis bacteria per dose. | 10-02-2008 |
| 20080254068 | Novel Vaccine for Veterinary and Human Medicine Prophylaxis and Therapy - The present invention relates to a novel vaccine, its use for immunoprophylaxis and/or the treatment of candidamycoses in human and veterinary medicine as well as methods for its preparation, wherein said vaccine consists of the combination of the | 10-16-2008 |
| 20080254069 | VACCINES FOR IMMUNIZATION AGAINST HELICOBACTER - The invention relates to the immunisation of pigs against | 10-16-2008 |
| 20080267998 | Combinations of gene deletions for live attenuated shigella vaccine strains - vaccine strains whose primary attenuating feature is deletion of the virG(icsA) gene and additional two or more deletions in setAB(shET1), senA(shET2), senB(shET2-2), stxAB, and msbB2 genes. Thus, the vaccine strain will have three or more deletions in the identified genes, will be safer, and will reduce or eliminate symptoms of fever and diarrhea in humans. The following specific vaccine strains have been constructed: WRSS3 (ΔsenA, ΔsenB, ΔvirG, ΔmsbB2), WRSf2G15 (ΔvirG, ΔsetAB, ΔsenA, ΔsenB, ΔmsbB2), and WRSd5 (ΔvirG, ΔstxAB, ΔsenA, ΔsenB, ΔmsbB2). | 10-30-2008 |
| 20080279893 | Lawsonia intracellularis immunological proteins - The present invention provides nucleic acid and amino acid sequences useful as the immunogenic portion of vaccines or immunogenic compositions effective for lessening the severity of the clinical symptoms associated with | 11-13-2008 |
| 20080279894 | Bacterial Glycolipid Activation of Cd1d-Restricted Nkt Cells - Disclosed are methods for activating an NKT cell, methods of stimulating an immune response in a subject, methods of improving vaccine efficacy, and methods of treating an infection. Also disclosed are methods of promoting tumor rejection, treating cancer, modulating autoimmunity and inhibiting allergen-induced hypersensitivity in subjects. The methods include contacting an NKT cell with a bacterial glycolipid complexed with a CD1 molecule to activate the NKT cell. The bacterial glycolipid may be derived from a member of the Class Alphaproteobacteria. | 11-13-2008 |
| 20080286309 | Process for Preparing Variant of Erysipelothrix Rhusiopathiae Surface Protective Antigen in E. Coli - A variant of | 11-20-2008 |
| 20080317781 | Vaccines for diseases of fish - Fish are immunized by a mass vaccination method, such as by immersion in water containing an attenuated strain of a pathogenic bacterium that does not effectively cause disease in fish when the non-attenuated pathogenic bacterium is exposed to the fish by immersion. An illustrative example of the method is for immunizing against coldwater disease caused by | 12-25-2008 |
| 20090004223 | Capsule composition for use as immunogen against campylobacter jejuni - An immunogenic composition, and method of using the composition to elicit an immune response to | 01-01-2009 |
| 20090035329 | DIAGNOSTIC AND TREATMENT METHODS FOR CHARACTERIZING BACTERIAL MICROBIOTA IN SKIN CONDITIONS - The present invention relates to methods for characterization of bacterial skin microbiota to provide diagnostic, therapeutic, and preventive measures for alleviating skin conditions. In certain embodiments, the invention relates to characterization of bacterial skin microbiota associated with psoriasis and related diagnostic, therapeutic, and preventive measures for alleviating psoriasis. These methods will be useful for detecting, diagnosing, and monitoring individuals who have or are at risk of certain skin conditions. | 02-05-2009 |
| 20090060952 | PRODUCTION OF THE LIPIDATED FORM OF THE PEPTIDOGLYCAN-ASSOCIATED LIPROPROTEINS OF GRAM-NEGATIVE BACTERIA - The expression of the lipidated form of the peptidoglycan-associated protein (PAL) of gram-negative bacteria is achieved through the use of a plasmid containing a tightly regulated promoter. A bacterial host cell is transformed, transduced or transfected with such a plasmid. The host cell is then cultured under conditions such that the lipidated recombinant PAL is expressed. The lipidated recombinant PAL is included in an antigenic composition administered to a mammalian host to immunize against a gram-negative bacterium. | 03-05-2009 |
| 20090074817 | TYPE III SECRETION PATHWAY IN AEROMONAS SALMONICIDA, AND USES THEREFOR - Disclosed is a newly identified and characterized type III secretion system in | 03-19-2009 |
| 20090087456 | ADJUVANTED VACCINE - This invention relates to new immunogenic compositions and vaccines suitable for preventing or treating tularemia. | 04-02-2009 |
| 20090098163 | Mutant F. turlarensis strain and uses thereof - A mutant strain of | 04-16-2009 |
| 20090104232 | COMPOSITIONS AND METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST YERSINIA PESTIS - The invention provides a gene transfer vector for inducing an immune response against | 04-23-2009 |
| 20090136546 | IMMUNOMODULATING COMPOSITIONS AND USES THEREFOR - The present invention discloses the use of an inhibitor of IL-10 function and an immune stimulator that stimulates the priming of an immune response to a target antigen, in methods and compositions for stimulating and prolonging host immune responses to the target antigen. The methods and compositions of the present invention are particularly useful in the treatment or prophylaxis of a range of conditions including pathogenic infections and cancers. | 05-28-2009 |
| 20090142374 | COMPOSITION FOR IMMUNOSTIMULATION - The present invention relates to a composition for immunostimulation useful for promoting IgA and secretory component productions in mucosal tissues, comprising, alone or in combination, a cell of bifidobacterium belonging to | 06-04-2009 |
| 20090142375 | LIPOTEICHOIC ACID FROM LACTIC ACID BACTERIA AND ITS USE TO MODULATE IMMUNE RESPONSES MADIATED BY GRAM-NEGATIVE BACTERIA, POTENTIAL PATHOGENIC GRAM-POSITIVE BACTERIA - The invention relates to a composition for modulating the immune responses induced by Gram negative bacteria, potential pathogenic Gram positive bacteria and/or their derivatives, comprising lipoteichoic acid from lactic acid bacteria as an active ingredient. It also relates to the use of a lipoteichoic acid from lactic acid bacteria as an active ingredient and/or lactic acid bacteria producing it and/or its supernatant of culture, in the manufacture of a medicament, an oral or topical product for cosmetic, dermatological or ophtalmological applications, a food or petfood composition for modulating bacterial colonisation, immune responses and decreasing the inflammatory processes associated with bacterially-mediated disease and infection in the gastrointestinal tract, bone, skin, eye, ear, lung and oral cavity. The invention also relates to lipoteichoic acid selected thereof. | 06-04-2009 |
| 20090155313 | Vaccine Against Salmonid Rickettsial Septicaemia Based on Arthrobacter Cells - A vaccine based on live | 06-18-2009 |
| 20090186051 | Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof - This invention provides recombinant polypeptides comprising a fragment of a High Molecular Weight Melanoma-Associated Antigen (HMW-MAA), recombinant | 07-23-2009 |
| 20090220548 | Immunogenic Agents Against Burkholderia Psudomallei And/Or Burkholderia Mallei, Comprising Lipopolysaccharide, Capsular Polysaccharide And/Or Proteins From Burkholderia Pseudomallei - An immunogenic agent which comprises a killed strain of | 09-03-2009 |
| 20090232848 | METHODS FOR CULTIVATING LAWSONIA INTRACELLULARIS - This invention relates to methods for cultivating | 09-17-2009 |
| 20090238845 | ENCAPSULATED VACCINES FOR THE ORAL VACCINATION AND BOOSTERING OF FISH AND OTHER ANIMALS - The invention relates to a composition comprising a pharmaceutically active agent and a bioadhesive delivery system that provides for the oral delivery of a vaccine to animals, particularly aquatic animals. | 09-24-2009 |
| 20090258037 | VACCINE DEVELOPMENT STRATEGY USING MICROGRAVITY CONDITIONS - Methods are provided herein for producing a vaccine, comprising culturing bacteria in microgravity. In some examples, the method includes culturing bacteria in microgravity, evaluating RNA expression, detecting an RNA that is over- or underexpressed during culture in microgravity, deleting the over- or underexpressed RNA in bacteria, and killing or attenuating the bacteria to produce a vaccine. In other examples, the method comprises culturing bacteria in microgravity, evaluating RNA expression, detecting a RNA that is over- or underexpressed during culture in microgravity, selecting bacteria that over- or underexpress the RNA, culturing the selected bacteria, and killing the bacteria to produce a vaccine. Vaccine compositions produced by the disclosed methods are also contemplated. | 10-15-2009 |
| 20090285856 | HELICOBACTER SPECIES AND CULTIVATION THEREOF - The present invention relates to the isolation and cultivation of “Candidatus | 11-19-2009 |
| 20090285857 | RECOMBINANT CHIMERIC ANTIGENS FOR DIAGNOSIS AND PREVENTION OF SCRUB TYPHUS - Recombinant chimeric antigens comprising unmodified and modified reactive polypeptide fragments of expressed product of the recombinant 56 kDa proteins of multiple strain of scrub typhus, such as Karp, Kato (Ktr56), Gilliam (Gmr56), and TA763 (TAr56). The invention is useful for detecting prior exposure to a number of strains of scrub typhus, based on the strength of reaction toward the chimeric protein and as a component in vaccine formulations and production of immune globulins for passive prophylaxis and immunity in subjects against heterologous infections. | 11-19-2009 |
| 20090324646 | Targeting the Histone Code as a Bacterial Strategy for Selectively Modulating Gene Expression - The ospF gene of | 12-31-2009 |
| 20100021501 | LIVE VACCINE STRAINS OF FRANCISELLA - A strain of | 01-28-2010 |
| 20100040652 | LIVE ATTENUATED CATFISH VACCINE AND METHOD OF MAKING - A high throughput bioluminescence mutant screening procedure is disclosed. This procedure utilizes robotics, and bacterial luciferase to allow real-time monitoring of mutant viability. The procedure was used to decelop a live attenuated vaccine for a catfish against | 02-18-2010 |
| 20100047283 | FRANCISELLA STRAIN FOR LIVE VACCINE - A strain of | 02-25-2010 |
| 20100062021 | VACCINATION FOR LAWSONIA INTRACELLULARIS - The present invention include a method of protecting an animal against | 03-11-2010 |
| 20100062022 | IMMUNOGENIC PROTEINS OF BURKHOLDERIA PSEUDOMALLEI AND USES THEREOF - A protein derived from an outer layer of | 03-11-2010 |
| 20100062023 | CHOLESTEROL-CONTAINING COMPOUNDS AND THEIR USE AS IMMUNOGENS AGAINST BORRELIA BURGDORFERI - Unique compounds that can be used for inducing an immune response to | 03-11-2010 |
| 20100074921 | CARRIER - The present invention is directed to providing a carrier which can transport a compound to a gut-associated lymphoid tissue efficiently without being degraded or digested. For that purpose, the carrier contains a coccoid cell of a gastric mucosa-damaging spiral bacterium. Preferably, the carrier is orally administered. By making this carrier carry an antigen and orally administering it, a local or a systemic immunological reaction to the antigen can be induced. | 03-25-2010 |
| 20100080828 | IMMUNOGENIC SEQUENCES - The application relates to nucleic acids which encode enzymes responsible for the production of the O-antigen of | 04-01-2010 |
| 20100092516 | BACTERIAL GHOST (BG) PRODUCTION PROCESS USING BETAPROPIOLACTONE (BPL) FOR FINAL INACTIVATION - The invention relates to bacterial ghost preparation using betapropiolactone for final inactivation of bacteria. | 04-15-2010 |
| 20100104601 | TREATMENT OF IMMUNE DISEASE BY MUCOSAL DELIVERY OF ANTIGENTS USING GENETICALLY MODIFIED LACTOBACILLUS - The present invention relates to the treatment of autoimmune and allergic diseases by mucosal delivery by micro-organism, in particular | 04-29-2010 |
| 20100112002 | Modified Pathogens for Use as Vaccines - Described herein are microorganisms that are modified so that they have an increased ability to be recognized by the innate immune system of a eukaryote, relative to an unmodified microorganism. A microorganism may be a gram-negative bacterium that has been modified to produce high potency lipopolysaccharide, e.g., | 05-06-2010 |
| 20100112003 | BIFIDOBACTERIUM IN THE TREATMENT OF INFLAMMATORY DISEASE - A strain of | 05-06-2010 |
| 20100112004 | HYPOXIA INDUCIBLE FACTOR INDUCER AND METHODS FOR USING THE SAME - The present invention provides vaccine compositions and methods for using the same. Generally, the vaccine is used to prevent infection of a microorganism that produces an HIF inducing compound. Accordingly, vaccines of the invention comprise at least a portion of an HIF inducing compound that is produced by the microorganism. | 05-06-2010 |
| 20100119553 | Helicobacter pylori sialic acid binding adhesin, SabA and sabA - gene - An isolated | 05-13-2010 |
| 20100143411 | METHOD FOR IDENTIFICATION OF T-LYMPHOCYTE ANTIGENS - A method for high-throughput identification of antigens is disclosed. The method involves generating transcriptionally active PCR (TAP) products of one or more antigen candidates and expressing the TAP products in an in vitro translation transcription (IVTT) system. The TAP products are purified using identifiable tags. The purified TAP products are presented to isolated antigen-presenting cells (APCs), which are in turn are presented to T-cells. The ability of the antigen candidates to induce activation of the T-cells is determined. Activation of the T-cells identifies the antigen candidate as an antigen. Immunogenic compositions and methods of treatment using such compositions are also disclosed. | 06-10-2010 |
| 20100143412 | BASB027 PROTEINS AND GENES FROM MORAXELLA CATARRHALIS, ANTIGENS, ANTIBODIES, AND USES - The invention provides BASB027 polypeptides and polynucleotides encoding BASB027 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. | 06-10-2010 |
| 20100150964 | POLYPEPTIDES AND METHODS FOR THE SPECIFIC DETECTION OF ANTIBODIES IN PATIENTS WITH A BORRELIA INFECTION - The present disclosure relates to proteins derived from OspC from bacteria of the genus | 06-17-2010 |
| 20100172938 | MODIFIED BACTERIAL SURFACE LAYER PROTEINS - Modified bacterial surface layer (S-layer) proteins are disclosed where the modification is the insertion, at an internal location, of a heterologous polypeptide, or polypeptide of interest. The polypeptide is a binding or target protein, such as an antigen or antibody, or part thereof, in particular a bacterial antigen (e.g. from | 07-08-2010 |
| 20100183674 | COMPOSITIONS COMPRISING YERSINIA PESTIS ANTIGENS - Disclosed are several | 07-22-2010 |
| 20100221286 | Modified live aeromonas hydrophila vaccine for aquatic animals - Safe and effective live vaccines against | 09-02-2010 |
| 20100221287 | Streptococcus pneumoniae Polynucleotides and Sequences - The present invention provides polynucleotide sequences of the genome of | 09-02-2010 |
| 20100221288 | NOVEL STREPTOCOCCUS PNEUMONIAE OPEN READING FRAMES ENCODING POLYPEPTIDE ANTIGENS AND USES THEREOF - The present invention relates to newly identified open reading frames comprised within the genomic nucleotide sequence of | 09-02-2010 |
| 20100233211 | ATTENUATED FRANCISELLA AND METHODS OF USE - is the bacterial pathogen that causes tularemia in humans and a number of animals. To date, no approved vaccine exists for this widespread and life-threatening disease. The present disclosure provides attenuated | 09-16-2010 |
| 20100233212 | METHODS AND COMPOSITIONS USING LISTERIA FOR ENHANCING IMMUNOGENICITY BY PRIME BOOST - Provided herein are prime-boost regimens and materials used therein. The prime-boost regimens enhance the immune response to a target antigen. The vaccines used for boost are comprised of recombinant attenuated metabolically active | 09-16-2010 |
| 20100239613 | ATTENUATED EHRLICHIOSIS VACCINE - The present invention relates to an attenuated strain of | 09-23-2010 |
| 20100247575 | AGENTS FOR PROMOTING IGA PRODUCTION - The present invention provides | 09-30-2010 |
| 20100266637 | METHOD OF PREVENTING EARLY LAWSONIA INTRACELLULARIS INFECTIONS - The present invention relates inter alia to the use of a combination of a vaccine against | 10-21-2010 |
| 20100278866 | BORRELIA DIAGNOSTICS AND SCREENING METHODS - Compositions and methods of detecting | 11-04-2010 |
| 20100285067 | INTERFERON-BETA PRODUCTION MODULATING LISTERIA STRAINS AND METHODS FOR USING SAME | 11-11-2010 |
| 20100285068 | METHOD FOR THE INTERNALIZATION OF NON-INVASIVE BACTERIA IN EUKARYOTE CELLS - The present invention relates to the use of adenylate cyclase toxin (ACT), or a functionally equivalent variant thereof, as an inducing agent for the internalization of non-invasive bacteria in eukaryotic cells. Due to ACT, said non-invasive bacterium can move through the plasma membrane of a eukaryotic cell and transfer plasmid DNA to said cell, which is useful for releasing or introducing molecules of therapeutic interest, for example, antigens, in the interior of the eukaryotic cell, thereby triggering the immune response. | 11-11-2010 |
| 20100291148 | Shigella mutants in the functions pertaining to the processes of maturing and recycling peptidoglycans and their uses as immunogens - Bacteria belonging to the | 11-18-2010 |
| 20100291149 | ATTENUATED LISTERIA SPP. AND METHODS FOR USING THE SAME - Attenuated | 11-18-2010 |
| 20100297178 | NOVEL GENES AND PROTEINS OF BRACHYSPIRA HYODYSENTERIAE AND USE OF SAME FOR DIAGNOSIS AND THERAPY - Novel polynucleotide and amino acids of | 11-25-2010 |
| 20100297179 | Immunology Treatment for Biofilms - The invention provides a composition for use in raising an immune response to | 11-25-2010 |
| 20100303861 | Live Attenuated Vaccine Strain for Prevention of Tularemia - The invention provides live attenuated avirulent strains of | 12-02-2010 |
| 20100303862 | INCAPACITATED WHOLE-CELL IMMUNOGENIC BACTERIAL COMPOSITIONS PRODUCED BY RECOMBINANT EXPRESSION - The present invention features incapacitated whole-cell bacterial immunogenic compositions and methods of their production, which compositions are useful to deliver antigens in a manner resembling the live infectious organism in terms of elicitation of a robust immune response, but with reduced risk or no risk of disease. The compositions of the invention are produced by rendering a bacterium bacteriostatic through expression of a recombinant promoter in the bacterial cell, which promoter can be operably linked to a polynucleotide encoding a recombinant gene product. In one embodiment, where the bacterium is a gram negative host, the recombinant gene product provides for reduced toxicity of LPS. In one embodiment, the gene product is a bacteriophage protein, such as endolysin, holin, or ndd. | 12-02-2010 |
| 20100303863 | RECOMBINANT EDWARDSIELLA BACTERIUM - The present invention encompasses a recombinant | 12-02-2010 |
| 20100322973 | ANTI-ALLERGIC AGENT - Provided is an antiallergic agent including, as an active ingredient, a fermentation product of a propionic acid bacterium. | 12-23-2010 |
| 20110008388 | PIGLET FEED RATIONS HAVING LOW LEVELS OF FERMENTABLE CARBOHYDRATES - The present invention provides compositions comprising at least one acidifying agent, at least one immune stimulating agent, at least one antioxidant, and optionally, at least one tissue regeneration agent. The compositions comprise pre-mixes for inclusion in the diets of piglets, wherein the diets have low levels of fermentable carbohydrates. | 01-13-2011 |
| 20110020399 | Vaccines and Immunomodulatory Therapies for Tularemia - The present invention relates to attenuated strains of | 01-27-2011 |
| 20110020400 | PROBIOTIC BIFIDOBACTERIUM STRAINS | 01-27-2011 |
| 20110020401 | TISSUE TARGETED ANTIGENIC ACTIVATION OF THE IMMUNE RESPONSE TO TREAT CANCERS - The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. The formulations of the invention thereby facilitate activation of an immune response to a cancer in a particular tissue or organ. The compositions may for example include killed or attenuated microbial pathogens, such as whole killed bacterial cells, and may be administered at sites distant from the cancer, for example the skin. In some embodiments, microbial species of endogenous flora that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions. In alternative embodiments, exogenous microbial pathogens that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions. The administration of the immunogenic compositions may be repeated relatively frequently over a relatively long period of time. In embodiments for intradermal or subcutaneous injection, dosages may be adjusted so that injections reproduce a consistent, visible, delayed inflammatory immune reaction at the successive site or sites of administration. | 01-27-2011 |
| 20110027319 | METHODS OF ELICITING OR BOOSTING A CELLULAR IMMUNE RESPONSE - Site-specific | 02-03-2011 |
| 20110038891 | NOVEL LACTIC ACID BACTERIUM HAVING ANTI-ALLERGIC ACTIVITY, ANTI-ALLERGIC AGENT, FOOD AND PHARMACEUTICAL COMPOSITION EACH COMPRISING THE LACTIC ACID BACTERIUM, AND PROCESS FOR PRODUCTION OF THE ANTI-ALLERGIC AGENT - An object aims to develop a lactic acid bacterium having an anti-allergic activity, which can be grown by using rice, particularly polished white rice, and can be collected, cooked and ingested together with rice in such a state that the lactic acid bacterium is attached to the surface of the rice. Another object aims to develop a food composition and a pharmaceutical composition, each of which comprises rice containing the lactic acid bacterium as a material. Thus, disclosed are: a lactic acid bacterium | 02-17-2011 |
| 20110052635 | LIVE ATTENUATED SALMONELLA VACCINE - The present invention is related to double and triple attenuated mutant strains of a bacterium infecting veterinary species such as | 03-03-2011 |
| 20110110981 | Orally Administerable Vaccine for Yersinia Pestis - Disclosed herein is the successful expression of the plague F1-V fusion antigen in chloroplasts. Parenteral and/or oral administration of chloroplast produced antigens effectively elicit protective immune responses in vivo. Disclosed herein is the first report of a plant-derived oral vaccine that protected animals from live | 05-12-2011 |
| 20110117130 | Method of diagnosing and treating Ehrlichia - The present invention provides an isolated and purified heat shock protein 60 (Hsp60) peptide having the amino acid sequence of SEQ ID NO:2. The instant invention is also directed to a vaccine against | 05-19-2011 |
| 20110117131 | Production of OspA for Lyme Disease Control - The present invention relates, generally, to the production of one or more OspA proteins in plant cells. Heterologous DNA comprising genes encoding one or more desired OspA protein(s) are introduced into plant cells. The one or more OspA protein(s) can be recombinantly-produced in the plant cells, optionally purified from the plant cells, and used as an oral vaccine to prevent the transmission of Lyme disease, particularly by animal vectors. The recombinantly-produced OspA protein(s) can be provided in oral and parenteral formulations. The present invention also relates to oral administration of OspA protein(s) to vaccinate against Lyme disease. The OspA protein(s) may be provided in a dosage form that is suitable for oral administration as a vaccine to prevent an animal from developing Lyme disease after exposure to a source of | 05-19-2011 |
| 20110123570 | ACTINOBACILLUS SUIS ANTIGENS - The invention provides immunogenic compositions useful for inhibiting, treating, protecting, or preventing infection by | 05-26-2011 |
| 20110123571 | USE OF BACTERIUM FOR MANUFACTURE OF A VACCINE - The present inventon relates to the use of live attenuated bacteria for the manufacture of a vaccine for submucosal administration. | 05-26-2011 |
| 20110129499 | DUAL DELIVERY SYSTEM FOR HETEROLOGOUS ANTIGENS - Provided herein are recombinant | 06-02-2011 |
| 20110129500 | LAWSONIA INTRACELLULARIS BACTERIUM OF A NOVEL SEROTYPE, VACCINE BASED ON THAT BACTERIUM, ANTIBODIES SUITABLE FOR DIAGNOSING THE NOVEL LAWSONIA INTRACELLULARIS SEROTYPE AND HYBRIDOMAS FOR PRODUCING THE SAID ANTIBODIES - This invention pertains to | 06-02-2011 |
| 20110135689 | Vaccine, therapeutic composition and methods for treating or inhibiting francisella tularenis - The present invention is directed to compounds and methods for treating a mammal exposed to | 06-09-2011 |
| 20110177126 | BACTERIA AND DERIVED PRODUCTS TO REINFORCE THE BODY DEFENCES AND TO REDUCE THE RISK OF DISEASE - This invention relates to a new strain of the genus | 07-21-2011 |
| 20110200637 | Immunizing Compositions and Methods of Use - The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions. | 08-18-2011 |
| 20110229521 | NUTRITIONAL SUPPORT OF THE IMMUNE SYSTEM DURING ANTI-CANCER TREATMENT - The present invention relates to methods and immunonutritional compositions for preventing the impairment of the immune function during anti-cancer therapy, thereby attaining a better efficacy of the treatment. More particularly, the present invention relates to methods and immunonutritional compositions that can transiently augment or enhance the immunocompetence of an immune cell and the immunogenecity of a tumor cell of a subject undergoing anti-cancer therapy-induced apoptosis and tumor-cell-enhanced immunogenicity such that the innate and adaptive immune functions and normal physiology of the immune cell are preserved, which, in turn, lead to (i) a better tolerance and increased efficacy to anti-cancer therapy; (ii) transient augmentation or enhancement of immunocompetence of the immune cell and immunogenecity of the tumor cell; and (iii) optimization of the effects of and increase of immunocompetence of the immune cell weakened by anti-cancer therapy. | 09-22-2011 |
| 20110236423 | IMMUNOGENIC AGENTS AGAINST BURKHOLDERIA PSEUDOMALLEI AND/OR BURKHOLDERIA MALLEI, COMPRISING LIPOPOLYSACCHARIDE, CAPSULAR POLYSACCHARIDE AND/OR PROTEINS FROM BURKHOLDERIA PSEUDOMALLEI - An immunogenic agent which comprises a killed strain of | 09-29-2011 |
| 20110243990 | Vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias - The invention relates to vaccines for treating prostate inflammation and benign prostate hyperplasias (stages I and II) comprising | 10-06-2011 |
| 20110256177 | YERSINIA PESTIS VACCINE - The present invention encompasses a recombinant | 10-20-2011 |
| 20110256178 | BORRELLIA BURGDORFERI BACTERIN - A bacterin including effective immunizing amounts of two non-crossprotective isolates of inactivated | 10-20-2011 |
| 20110274722 | FOOD CONTAINING A PROBIOTIC AND AN ISOLATED BETA-GLUCAN AND METHODS OF USE THEREOF - The invention features a food product containing a probiotic and β-glucan isolated from a natural source, methods of treating a disease or disorder by administering the food product, and a package containing separated components of the food product. | 11-10-2011 |
| 20110293661 | VACCINE STRAINS OF BRACHYSPIRA HYODYSENTERIAE - The present invention relates generally to vaccine strains of | 12-01-2011 |
| 20110305728 | DRUG FOR TREATING INFECTIONS - The invention relates to the use of glycoproteins extracted from the | 12-15-2011 |
| 20120009218 | Attenuated Gram Negative Bacteria - Disclosed and claimed are a mutant of a gram negative bacterium, wherein said bacterium has at least one mutation in a nucleotide sequence which codes for a polypeptide having an identity which is equal or more than 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% with an amino acid sequence coded by a nucleotide sequence selected from the group consisting of nucleotide sequences identified SEQ ID NO: 2, 6, 9, 12, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 75, 78, 81, 84, 87, 90, 93; said mutation resulting in attenuated virulence of the bacterium. Immunogenic compositions and vaccines containing such a mutant are also disclosed and claimed. | 01-12-2012 |
| 20120034268 | BACTERIAL GHOSTS FOR MEDIATING INNATE IMMUNITY - The invention relates to the use of bacterial ghosts (BG) to promote an innate immune response. | 02-09-2012 |
| 20120045474 | Substrate peptide sequences for plague plasminogen activator and uses thereof - The present invention is directed to peptide sequences that were identified from combinatorial libraries and could serve as substrates of plague plasminogen activator (Pla). Another aspect of the present invention is drawn to peptides derived from the substrates for Pla as a result of chemical modifications leading to specific inactivation of the proteolytic activity of Pla. Additionally, the present invention is directed to the use of the substrates identified herein in the detection of bacteria expressing omptin family of proteases which includes | 02-23-2012 |
| 20120045475 | LIVE ATTENUATED VACCINES - The present invention relates to a bacterium attenuated by a mutation in at least one ABC transporter gene wherein the mutation renders the corresponding ABC transporter protein non-functional and wherein the attenuated bacterium persists in a subject. | 02-23-2012 |
| 20120064118 | BACTERIA STRAINS HAVING A HIGH ANTI-INFLAMMATORY ACTIVITY - The present invention relates to probiotic bacteria strains having a high anti-inflammatory activity. The present invention relates to bacteria strains as strongly inducers of Interleukin-10 (IL-10) production. In particular, the present invention relates to the anti-inflammatory activity shown by said bacteria strains due to its enhancement of IL-10 production in peripheral blood mononuclear cells, with on the other hand a low capability to stimulate the production of the pro-inflammatory 11-12, thus leading to a high IL-10/IL-12 ratio. Further, the present invention relates to the use of at least one bacterium strain for the preparation of a composition for the prevention or treatment of the inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS). Finally, the present invention relates to food products, such as probiotic dietary supplements containing at least one probiotic bacterium strain, as an active ingredient. | 03-15-2012 |
| 20120076824 | NOVEL EDWARDSIELLA ICTALURI E-ICT-VL33 STRAIN, VACCINES THEREOF, AND A METHOD FOR PROTECTING FISHES USING SAID VACCINES | 03-29-2012 |
| 20120082698 | MUTANTS OF FRANCISELLA TULARENSIS AND USES THEREOF - The present invention relates to a mutant | 04-05-2012 |
| 20120087946 | RECOMBINANT BACTERIUM AND METHODS OF ANTIGEN AND NUCLEIC ACID DELIVERY - The present invention provides a recombinant bacterium and methods of using the recombinant bacterium to induce an immune response. | 04-12-2012 |
| 20120093864 | Methods and Compositions for Polytopic Vaccination - The present invention relates to therapeutic and prophylactic methods for treating Or preventing an infectious disease in a subject by stimulating or enhancing an immune response against an infectious agent causing the disease. The methods comprise administering to the subject a plurality of compositions, each composition being administered to a different site Of the subject, wherein each site is, or substantially drains to, an anatomically distinct lymph node, a group of lymph nodes, a nonencapsulated cluster of lymphoid tissue, or the spleen. Each composition comprises at least one antigenic molecule having one or more epitopes of the same infectious agent or a strain thereof. The antigenic molecules of each composition comprise in aggregate a set of epitopes distinct from that of any other composition that is administered to the subject. | 04-19-2012 |
| 20120128718 | ATTENUATED FNR DEFICIENT ENTEROBACTERIA - The invention provides an attenuated enterobacterium comprising an attenuating mutation in the fnr gene, and optionally further comprising a heterologous nucleic acid encoding a foreign antigen. Also provided are pharmaceutical formulations comprising the attenuated enterobacteria of the invention. Further disclosed are methods of inducing an immune response in a subject by administration of an immunogenically effective amount of an attenuated enterobacterium or pharmaceutical formulation of the invention. | 05-24-2012 |
| 20120135036 | BACTERIAL COMPOSITION AND ITS USE - The subject of the present invention is a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of | 05-31-2012 |
| 20120141530 | CANINE LYME DISEASE VACCINE - The present invention provides a vaccine for canine Lyme disease and methods of making and using the vaccine alone, or in combinations with other protective agents. | 06-07-2012 |
| 20120148623 | VACCINATION FOR LAWSONIA INTRACELLULARIS - The present invention include a method of protecting an animal against | 06-14-2012 |
| 20120177687 | GENE EXPRESSING A BIFIDOBACTERIUM SURFACE-PRESENTED FUSION PROTEIN - According to the present invention, there is provided a means of expressing and displaying a protein on the cell surface of a | 07-12-2012 |
| 20120189661 | VACCINES COMPRISING HEAT-SENSITIVE TRANSGENES - The present disclosure provides temperature sensitive essential nucleic acid molecules from a psychrophilic bacterium, proteins encoded by the nucleic acid molecules, as well as recombinant cells into which have been introduced such nucleic acid molecules. The disclosed recombinant cells containing one or more essential nucleic acid molecules from a psychrophilic bacterium are thereby made temperature sensitive, and can be administered to a mammal to induce an immune response in the mammal. | 07-26-2012 |
| 20120258138 | PROBIOTIC BACTERIAL STRAINS AND METHOD OF USE TO DECREASE MORTALITY IN FISH DUE TO BACTERIAL DISEASE - Two novel strains of bacteria, C6-6 and C6-8, deposited in accordance with the Budapest Treaty, protect fish, such as by reducing mortality, against disease caused by bacteria, such as coldwater disease caused by | 10-11-2012 |
| 20120269855 | TOLL-LIKE RECEPTOR 5 LIGANDS AND METHODS OF USE - The invention provides methods to elicit an immune response with an immunomodulatory flagellin polypeptide having toll-like receptor 5 (TLR5) binding, and further comprising an ADCC targeting molecule. | 10-25-2012 |
| 20120276143 | PROBIOTIC BIFIDOBACTERIUM STRAIN | 11-01-2012 |
| 20120288523 | ADMINISTRATION ROUTE FOR A COMPOSITION TO PROTECT AN ANIMAL AGAINST RHODOCOCCUS EQUI - The present invention pertains to the use of | 11-15-2012 |
| 20130011437 | Immune compositions for treating H. pylori infection - An immune composition for use, via topical administration, in eliciting Th2 or regulatory T cell-mediated immune responses specific to | 01-10-2013 |
| 20130064850 | Using Modified Plasmids to Suppress Antibiotic Resistant Pathogens - Methods of suppressing at least one species of micro-organism that is pathological to an organism. A first embodiment includes a method of suppressing at least one species of micro-organism that is pathological to an organism. A second embodiment includes a method of suppressing at least one species of micro-organism that is pathological to a mammal. A third embodiment includes a method of suppressing at least one species of bacteria that is pathological to a mammal. | 03-14-2013 |
| 20130071433 | Interferon- Production Modulating Listeria Strains and Methods for Using Same | 03-21-2013 |
| 20130071434 | Campylobacter Polypeptides and Methods of Use - The present invention provides isolated metal regulated polypeptides obtainable from a | 03-21-2013 |
| 20130078278 | VACCINE FOR PROTECTION AGAINST SHIGELLA SONNEI DISEASE - Compositions and methods for protecting a susceptable host against an infection of | 03-28-2013 |
| 20130156811 | METHOD OF PREVENTING EARLY LAWSONIA INTRACELLULARIS INFECTIONS - The present invention relates inter alia to the use of a combination of a vaccine against | 06-20-2013 |
| 20130164331 | ORAL VACCINATION OF FISH WITH LIVE ATTENUATED EDWARDSIELLA ICTALURI VACCINES - The present invention is directed to a novel live attenuated isolate and sub-isolets thereof of a strain of the pathogen | 06-27-2013 |
| 20130164332 | LAWSONIA VACCINE AND METHODS OF USE THEREOF - The present invention provides improved vaccination methods for increased protection against ileitis. The methods provide for the vaccination of young animals, preferably piglets, between 10 and 26 days of age, vaccination of pregnant sows during the second or third stages of gestation, and a combination of these methods. Vaccination of the pregnant sows can occur using repeated and/or high doses of | 06-27-2013 |
| 20130183343 | System and Method of Preparing and Storing Activated Mature Dendritic Cells - The present invention provides compositions and methods for generating and cryopreserving dendritic cells with superior functionality in producing stronger signals to T cells, resulting in a more potent DC-based anti-tumor vaccine. The present invention includes mature, antigen loaded DCs activated by Toll-like receptor agonists that induce clinically effective immune responses, preferably when used earlier in the disease process. The DCs of the present invention produce desirable levels of cytokines and chemokines, and further have the capacity to induce apoptosis of tumor cells. The cells can be cryopreserved and thawed for later use, thereby reducing the need for repeated pheresis and elutriation processes during vaccine production. These methods can also be utilized to directly target molecules involved in carcinogenetic signaling pathways and cancer stem cells. | 07-18-2013 |
| 20130202641 | IMMUNOLOGY TREATMENT FOR BIOFILMS - The invention provides a composition for use in raising an immune response to | 08-08-2013 |
| 20130224247 | VACCINE AGAINST EHRLICHIA CANIS - Vaccine and/or immunogenic compositions that comprise an effective immunizing amount of an | 08-29-2013 |
| 20130259899 | DETECTION OF FUSOBACTERIUM IN A GASTROINTESTINAL SAMPLE TO DIAGNOSE GASTROINTESTINAL CANCER - is a genus of gram-negative, filamentous, anaerobic bacteria found as normal flora in the mouth and large bowel, and often in necrotic tissue. A comparison of microbial ribonucleic acids (RNA) between colorectal carcinoma (CRC) tissue and adjacent normal control tissue found the over-representation of | 10-03-2013 |
| 20130266613 | OUTER MEMBRANE PROTEINS OF HISTOPHILUS SOMNI AND METHODS THEREOF - The present invention relates to immunological compositions of outer membrane proteins (OMPs) of | 10-10-2013 |
| 20130302372 | VACCINE FOR PROTECTION AGAINST LAWSONIA INTRACELLULARIS - The present invention pertains to the use of a non-live carbohydrate containing composition, the carbohydrate being also found in live | 11-14-2013 |
| 20130330374 | TREATMENT OF IMMUNE DISEASE BY MUCOSAL DELIVERY OF ANTIGENS USING GENETICALLY MODIFIED LACTOBACILLUS - The present invention relates to the treatment of autoimmune and allergic diseases by mucosal delivery by micro-organism, in particular | 12-12-2013 |
| 20140010842 | METHOD FOR MODULATING A BACTERIAL INVASION SWITCH - The subject matter disclosed herein pertains to the modulation of a bacterial invasion switch and the subsequent use of the bacterium to vaccinate an organism. In one embodiment, the bacterial invasion switch is modulated by changing the proteolysis of ExoR protein. In another embodiment, a mutated bacterium produces a mutant ExoR protein that resists proteolysis. | 01-09-2014 |
| 20140037685 | ADJUVANTS THAT ACTIVATE ADAPTIVE IMMUNE SYSTEM BY STIMULATING NLRP3 - A method of identifying an agent, or combination of agents, as a candidate immunological adjuvant is provided comprising contacting a cell comprising a Nod-like receptor (Nlrp3) with the agent. Methods of enhancing immune responses to vaccines are also provided. | 02-06-2014 |
| 20140037686 | LACTOBACILLUS PARACASEI NCC2461 (ST11) FOR USE BY PERINATAL MATERNAL ADMINISTRATION IN THE REDUCTION AND PREVENTION OF ALLERGIES IN PROGENY - The present invention provides a probiotic, | 02-06-2014 |
| 20140065186 | Immunostimulant for Animals, Feed Containing the Same, and Method for Producing the Same - By administering sterilized bacterial cells obtained by heat treating cells of a coryneform bacterium or an enterobacterium under a condition of pH 2 to 5 at 90 to 120° C. for 3 minutes to 4 hours, or a feed containing such sterilized bacterial cells to a mammal, fowl, fish, or crustacean, immunity of these animals is enhanced. | 03-06-2014 |
| 20140086954 | USE OF BLOOD OR TISSUE BACTERIOME FOR PREDICTION, DIAGNOSIS AND PREVENTION OF METABOLIC DISEASES AND THEIR CARDIOVASCULAR COMPLICATIONS - The present invention relates to the use of the bacterial flora for vaccine development, identification of therapeutic targets and prediction and/or diagnosis of metabolic diseases, such as diabetes, overweight and obesity, and their cardiovascular complications. In particular, the present invention provides immunogenic or vaccinal composition for preventing metabolic diseases and cardiovascular complications using attenuated or inactivated bacterial flora, or antigens derived thereof. The present invention also provides methods for identifying prognostic markers for metabolic diseases onset and cardiovascular complications and methods for in vitro prognosis of metabolic diseases and cardiovascular complications using bacterial flora. | 03-27-2014 |
| 20140086955 | Attenuated Live Vaccines for Aquatic Animals - Safe and effective live vaccines against bacteria infecting aquatic animals were created through the induction of novobiocin-resistance in liquid culture and novobiocin- and rifampicin-resistance in liquid culture. | 03-27-2014 |
| 20140120137 | LACTIC ACID BACTERIA AND THEIR USE IN SWINE DIRECT-FED MICROBIALS - TRFs useful for identifying strains of interest are provided. A method of identifying one or more strain that can be used as a direct-fed microbial is also provided. One or more strain identified by the method is additionally provided. A method is also provided for administering to an animal an effective amount of the one or more strain. Additionally provided is an isolated strain chosen from at least one of | 05-01-2014 |
| 20140141044 | Cord Colitis Syndrome Pathogen - The present invention provides a novel cord colitis syndrome pathogen as well as a method for the discovery of novel viral, prokaryotic or eukaryotic genomes or genomic fragments using a sequencing-based methodology. | 05-22-2014 |
| 20140147467 | Novel broth medium and blood free solid media - The present invention relates to new contamination resistant artificial media for the routine cultivation of | 05-29-2014 |
| 20140161838 | Yersinia spp. Polypeptides and Methods of Use - The present invention provides isolated polypeptides isolatable from a | 06-12-2014 |
| 20140178433 | LEPTOSPIRA WITH INCREASED ANTIGENIC MASS - The antigenic mass of | 06-26-2014 |
| 20140199346 | THERAPEUTIC AGENT FOR INFLUENZA VIRUS INFECTION DISEASES - Provided is a therapeutic agent for an influenza virus infectious disease, which utilizes an active ingredient derived from a natural product and has an excellent effect. The therapeutic agent for an influenza virus infectious disease includes, as an active ingredient, a β-glucan-containing composition obtained from a culture of a microorganism belonging to | 07-17-2014 |
| 20140220077 | New Modified Live Flavobacterium Strains, Stabilized Vaccines Comprising Same, and Methods of Making and Use Thereof - The present invention provides attenuated | 08-07-2014 |
| 20140234373 | Methods of Promoting Immune Tolerance - Compositions including a polynucleotide combined with a vehicle and methods of their use to induce a suppressive immune response are provided. In some embodiments the compositions induce an increase in expression of indoleamine 2,3 dioxygenase (IDO) enzyme activity in cells. The methods and compositions can be used to inhibit or reduce immune-mediated tissue destruction, to treat autoimmune diseases and inflammatory responses, to promote immune tolerance, to enhance tolerizing vaccines, to treat allergies, to treat asthma, or to enhance mucosal tolerance in subject. Methods and compositions for inducing a suppressive immune response for while minimizing undesirable side effects in the subject are also provided. An exemplary undesirable side effect is systemic release of INFγ. Exemplary compositions that can be used to induce an immune response in a subject without inducing systemic release of INFγ include compositions containing a polynucleotide lacking an immunostimulatory nucleic acid sequence complexed with a carrier. | 08-21-2014 |
| 20140242116 | Spray Dried Compositions and Methods of Use - Provided herein are insoluble particles that include polypeptides. The polypeptides may have immunogenicity that is greater than the immunogenicity of the same polypeptides when they are not present in the particle. The polypeptides may be soluble before incorporation into the particles and insoluble after incorporation into the particles. The particles may include lipopolysaccharide, wherein the lipopolysaccharide is insoluble. The particles may include a carrier. In one embodiment, a carrier is present at no greater than 0.001 mg carrier/mg particles. In one embodiment, a carrier is present at a ratio of carrier to polypeptide (weight:weight) of no greater than 0.05:1. In one embodiment, a carrier is not detectable in the particles. | 08-28-2014 |
| 20140286996 | Modified Gram-Negative Bacteria For Use As Vaccines - The invention relates to Gram-negative bacteria carrying an inactivated gene encoding a glycosyltransferase involved in the synthesis of the core of the LPS of said Gram-negative bacteria, wherein said inactivated gene results in the synthesis of a LPS having a modified core. These strains have an attenuated virulence but induce a humoral immunity sufficient for ensuring vaccination of the host. | 09-25-2014 |
| 20140302093 | MICROORGANISMS CARRYING A TUMOR ANTIGEN - The present invention pertains to microorganisms of the species | 10-09-2014 |
| 20140308314 | PHARMACEUTICAL COMPOSITION INCLUDING DEAD CELLS OF LACTOBACILLUS ACIDOPHILUS LB TO TREAT OR PREVENT ALLERGIC DISEASE - Provided is a pharmaceutical composition including dead cells of | 10-16-2014 |
| 20140322273 | STRAIN OF EXOPOLYSACCHARIDE-SECRETING LACTOBACILLUS PLANTARUM AND APPLICATION THEREOF - Provided is a strain of exopolysaccharide-secreting | 10-30-2014 |
| 20140328878 | MALLEABLE PROTEIN MATRIX AND USES THEREOF - The present invention relates to a malleable protein matrix (MPM), which is the reaction product of the agglomeration of proteins after a fermentation process and is exhibiting biological activities and is suitable for the incorporation (or encapsulation) of various hydrophilic or lipophylic substances. The present invention also relates to the process for the preparation of the malleable protein matrix and its usages. | 11-06-2014 |
| 20140328879 | PROBIOTIC BIFIDOBACTERIUM STRAINS | 11-06-2014 |
| 20140335127 | SYSTEM AND METHOD FOR THE PRODUCTION OF RECOMBINANT GLYCOSYLATED PROTEINS IN A PROKARYOTIC HOST - A system and a method for the production of recombinant N-glycosylated target proteins. The system comprises a prokaryotic organism (e.g. | 11-13-2014 |
| 20150017208 | LACTIC ACID BACTERIUM HAVING IMMUNOMODULATORY AND ANTI-ALLERGIC EFFECTS - A novel lactic acid bacterium strain having immunomodulatory and anti-allergic effects in a subject is disclosed. | 01-15-2015 |
| 20150030632 | FUSION PROTEIN FOR ENHANCING IMMUNOGENICITY OF BACTERIAL ANTIGEN/IMMUNOGEN - Establishment of an effective and uniform vaccine development strategy is key to conquering current and emerging infectious diseases. Despite successes against an array of bacterial agents, current approaches to vaccine development are as diverse as the microbes they target and require adjuvants that often have limited efficacy and/or toxic side effects. As a consequence, vaccine discovery is often slow, inefficient, and unsuccessful in the case of many high priority pathogens. The present disclosure suggests that vaccine generation for bacterial pathogens can be improved by optimizing the efficiency of processing/presentation of a bacterial immunogen via the targeting of immunogen to CR2 and/or TLR2 on APCs. This approach not only yields an adjuvant-free mucosal vaccine against a Category A biothreat agent, but also establishes a novel genetic approach/platform for vaccine development, which is applicable to many other infectious agents, thereby profoundly impacting preventive medicine/public health. | 01-29-2015 |
| 20150037372 | pH-Responsive High-Density Lipoprotein-Like Particle Complex - The present invention relates to a high-density lipoprotein (HDL)-like particle composite which is a drug-encapsulating apoA-I comprising apoA-I and a drug encapsulated in the apoA-I capable of releasing the drug encapsulated in the apoA-I under acidic pH conditions, and a preparation method thereof. Since the HDL-like particle composite of the present invention can release the encapsulated drug under acidic conditions, while remaining stable under non-acidic conditions over a wide temperature range, it can be widely used for the development of target-specific drugs. | 02-05-2015 |
| 20150140037 | Non-Replicating Bacterial Nanoparticle Delivery System and Methods of Use - The present invention provides compositions and methods for the secretion and the translocation of a compound of interest by a bacterial minicell. In certain embodiments, the invention provides a bacterial minicell comprising at least one component of the type III secretion system (T3SS), which provides a safe and efficient system for secretion and translocation. In one embodiment, the invention allows for the delivery of an antigen to a cell or subject in order to induce an immune response. | 05-21-2015 |
| 20150297703 | Bifidobacterium for dust mite allergy - A composition comprising | 10-22-2015 |
| 20150306199 | Leptospira With Increased Antigenic Mass - The antigenic mass of | 10-29-2015 |
| 20150313982 | METHODS AND COMPOSITIONS OF PROTEIN ANTIGENS FOR THE DIAGNOSIS AND TREATMENT OF LEPTOSPIROSIS - Novel immunodominant antigenic proteins and peptides associated with associated with leptospirosis were identified using a proteome array based on expression of ORFs from a | 11-05-2015 |
| 20150320849 | Method of treating central nervous system disorders with Borrelia burgdorferi antigen - The present invention relates to a treatment for mammalian subjects suffering from a central nervous system (CNS) disorder by administering a composition comprising an | 11-12-2015 |
| 20150351428 | METHODS AND COMPOSITIONS FOR ORALLY DOSING POSTNATAL SWINE - Swine pharmaceutical delivery compositions comprising an active agent and a pharmaceutically acceptable carrier, methods of preparing and administering the compositions, and kits for preparing and using the compositions are provided. | 12-10-2015 |
| 20160017409 | Compositions and Methods for Identifying Secretory Antibody-Bound Microbes - The invention relates to the identification of secretory antibody-bound bacteria in the microbiota in a subject that influence the development and progression of inflammatory diseases and disorders. Thus, the invention relates to compositions and methods for detecting and identifying the constituents of a subject's microbiota, methods of modifying the constituents of the microbiota, and methods for treating inflammatory diseases and disorders in a subject in need thereof. | 01-21-2016 |
| 20160022793 | COMPOSITIONS FOR TREATMENT AND/OR PREVENTION OF AUTOIMMUNE DISORDERS - The invention provides compositions for treating or preventing T1D (T1D), the compositions comprising one or more antigen presenting cells (APC) that have been pulsed with one or more bacteria and/or components of the bacteria, wherein the bacteria or their components confer upon the APCs the ability to inhibit the generation of diabetes-promoting T cells. The subject invention also provides a method of treating or preventing T1D in a subject, the method comprising administering APC that have been pulsed with one or more bacteria and/or components of the bacteria and wherein the bacteria or their components confer upon the APCs the ability to inhibit the generation of diabetes-promoting T cells. | 01-28-2016 |
| 20160106825 | VACCINE TO PROTECT AGAINST EHRLICHIA INFECTION - Certain embodiments are direct to a vaccine composition comprising an immunizing amount of an | 04-21-2016 |
| 20160158334 | IMMUNOMODULATORY MINICELLS AND METHODS OF USE - The present disclosure is related to immunomodulatory bacterial minicells and methods of using the minicells. | 06-09-2016 |
| 20160175429 | Immunotherapy Composition and Use Thereof | 06-23-2016 |
| 20160184418 | SWINE DYSENTERY VACCINE - The present invention relates to a composition comprising | 06-30-2016 |
| 20160199475 | LIVE-ATTENUATED VACCINE AGAINST PLAGUE | 07-14-2016 |
| 20180021422 | A VACCINE FOR USE AGAINST SUBCLINICAL LAWSONIA INFECTION IN A PIG | 01-25-2018 |
| 20220135986 | PHAGE-DERIVED PARTICLES FOR IN SITU DELIVERY OF DNA PAYLOAD INTO C. ACNES POPULATION - The invention relates to | 05-05-2022 |
